Symphony Medical has matched significant clinical and scientific resources in cardiology and electrophysiology with a proprietary portfolio of biopolymers, cell therapies, biotherapeutics, and surgical or catheter-based delivery devices.

Post-Op AFib	Prevention of post- operative atrial fibrillation
Cardiac Repair	Left Ventricular Reconstruction
Chronic AFib	Biologic treatment of atrial fibrillation

The result of this combination is Symphony Medical's core technology: the application of biotherapeutic and tissue engineering tools to the treatment of conduction abnormalities such as post-operative atrial fibrillation, atrial fibrillation, and left ventricular tachycardia.

With this biologic approach, Symphony Medical's products under development have the potential to offer safer, non-destructive, and self-regulating alternatives to ablation, pharmaceutical management, and implantable devices for the treatment of cardiac arrhythmias and cardiac repair.

Next to the greater safety and efficacy offered by non-destructive, biologic approaches, Symphony's product development efforts are guided by finding therapeutic solutions that are both practical and cost-effective. We invite you to learn more about our products in the following pages:

1. Symphony Medical's Kit for the prevention of post-operative atrial fibrillation
2. Biotherapeutics administered to the ventricular walls to support left ventricular reconstruction
   
3. Biotherapeutics injected to the perinodal region of the heart to slow atrioventricular conduction in atrial fibrillation